Using platelet function analysis to personalise anti-thrombotic drug therapies

PLatelet phenomics Analysis to guide patient Stratification and anti-platelet Medication In acute Coronary syndrome

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN67917825

Enrollment

400

Registered

2025-06-16

Start date

2026-01-01

Completion date

Unknown

Last updated

2025-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute coronary syndrome: non-STEMI myocardial infarction Circulatory System

Interventions

Platelet phenomics analysis to be performed at admission, at approximately 2 months (when likely to be on dual anti-platelet therapy) and at 12 months following removal of second anti-platelet agent

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Diagnosis of non-STEMI myocardial infarction

Exclusion criteria

Exclusion criteria: Patients already taking P2Y12 antagonists, pregnancy, active or recent malignancy, and renal, liver or other haematological pathologies

Design outcomes

Primary

Measure	Time frame
Platelet phenomics analysis to assess impact of inherent platelet function capacity on responses to single and dual anti-platelet therapies at baseline, 2 months, 12 months	—

Secondary

Measure	Time frame
Pharmacogenomic analysis to determine impact on platelet function responses (measured by Platelet Phenomic Analysis) of different anti-platelet agents at baseline, 2 months, 12 months	—

Countries

England, United Kingdom

Contacts

Public ContactJonathan Gibbins

j.m.gibbins@reading.ac.uk+44 1183787082

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026